Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data for zumilokibart in moderate-to-severe Atopic Dermatitis [AD]. APGE's half-life extended monoclonal antibody technology enables less frequent dosing, with Q3M and Q6M regimens showing EASI-75 responses of 75% and 85% in Week 16 responders. Upcoming catalysts include 16-week induction data from Part B of the phase 2 APEX trial in Q2 2026 and potential phase 3 initiation in H2 2026.